Prostate cancer cells have a marker on their surface called PSMA. It is a protein, a type II transmembrane protein, to be precise. Normal prostate cells have it. Cancerous prostate cells overexpress it. That difference is the entire basis for a drug called Lutetium (177Lu) vipivotide tetraxetan, or Pluvicto.
The drug is a radioconjugate. That is a fancy word for a delivery system. One part of the molecule, vipivotide tetraxetan, is the targeting ligand. It hunts down PSMA. The other part is the payload: lutetium-177, a beta-emitting radioisotope. The drug is injected intravenously. It finds the PSMA-positive tumor cells. It binds to them. Then it delivers beta particle radiation directly to those cells.
The key here is the targeting. Standard radiation therapy hits a broad area. Healthy tissue takes damage. This drug is different. The ligand seeks out the specific cells. The radiation is delivered locally. The surrounding healthy tissue is largely spared. That is the theory. That is the mechanism. That is why this drug matters.
The FDA approved Pluvicto in March 2022. The approval was for a specific group: patients with PSMA-positive metastatic castration-resistant prostate cancer, or mCRPC. That is a mouthful. It means the cancer has spread. It means hormone therapy has stopped working. It means options were running thin.
This is not a cure. It is a treatment. It is a targeted radioligand therapy. The drug company, Novartis, sells it under the brand name Pluvicto. The chemical name is longer: Lutetium (177Lu) vipivotide tetraxetan. Researchers also call it Lu-PSMA-617. The name does not matter much to a patient. What matters is that it works.
The clinical data that got the drug approved showed a survival benefit. Men who got the drug lived longer than men who got standard care. The numbers were clear enough for the FDA to give the green light. Since December 2022, the drug has been in active use. It is not a first-line treatment. It comes in after other therapies fail. But for those patients, it is a real option.
The science behind it is straightforward. PSMA is a tumor-associated antigen. It sits on the membrane of prostatic epithelial cells. In cancer, those cells multiply. The PSMA expression goes up. The drug exploits that. The ligand locks onto the antigen. The lutetium-177 does the killing. The beta particles have a short range. They hit the cancer cell and the cells immediately next to it. That is the antineoplastic activity in action.
This is precision medicine. It is not a blanket bomb. It is a guided missile. The guide is PSMA. The missile is the radioisotope. The whole thing is one molecule, injected into a vein, and sent to find its target.
The approval was a milestone. It was not the first radioligand therapy. But it was the first for this kind of prostate cancer. It opened a door. It showed that targeting a specific protein with a radioactive payload could work in a solid tumor. Other researchers are watching. Other cancers have markers. The same approach could apply elsewhere.
For now, the drug is for mCRPC. That patient population is not small. Prostate cancer is one of the most common cancers in men. Many will progress to the metastatic, castration-resistant stage. For them, Pluvicto is a new tool. It does not replace everything. It adds to the arsenal.
The drug has side effects. Radiation is radiation. Dry mouth, fatigue, low blood counts are possible. But the targeting limits the damage. The trade-off is acceptable for many patients. The FDA decided it was. The data supported it.
This is the story of a molecule. It has a long, technical name. It has a simple job: find the cancer, deliver the radiation, kill the cell. That is all. That is enough.
